DMD
Market Will Witness Intense Growth between 2014 and 2019
GlobalData estimates the 2014 sales for DMD reached approximately $8.2m across the 6MM, primarily driven by the sale of generic corticosteroids. By the forecast end in 2019, GlobalData expects a staggering growth in sales to at a Compound Annual Growth Rate (CAGR) of 160.5% across the 6MM over the five-year timeframe.
Major drivers of growth in the DMD market during the forecast period are attributed to:
• The introduction of novel, high-priced, disease-modifying therapies for DMD, such as PTC Therapeutics' Translarna, BioMarin/Prosensa Therapeutics' drisapersen, and Sarepta Therapeutics' eteplirsen.
• The strong demand from the patient community for an effective therapy for this fatal disease and a strong positive influence from patient advocacy groups on drug development, regulatory approval processes, and ultimately, drug uptake.
• The expected approval of repurposed molecules with broad specificity to treat DMD, such as Santhera Pharmaceutical's Catena (idebenone) and Eli Lilly's tadalafil.
• The label expansion of exon-51 skipping therapies (specifically, BioMarin/Prosensa Therapeutics' drisapersen and Sarepta Therapeutics' eteplirsen) to non-ambulant patients will substantially increase the size of the target patient pool for these drugs.
Read about the barriers to the growth of the DMD market http://www.marketinforesearch.com/opportunityanalyzer-duchenne-muscular-dystrophy-opportunity-market-analysis.html
Key Questions Answered
If you have any questions about this or any of our other reports, please do not hesitate to contact me:
Neelima Waugh
Marketing Executive
press@marketinforesearch.com
GlobalData estimates the 2014 sales for DMD reached approximately $8.2m across the 6MM, primarily driven by the sale of generic corticosteroids. By the forecast end in 2019, GlobalData expects a staggering growth in sales to at a Compound Annual Growth Rate (CAGR) of 160.5% across the 6MM over the five-year timeframe.
Major drivers of growth in the DMD market during the forecast period are attributed to:
• The introduction of novel, high-priced, disease-modifying therapies for DMD, such as PTC Therapeutics' Translarna, BioMarin/Prosensa Therapeutics' drisapersen, and Sarepta Therapeutics' eteplirsen.
• The strong demand from the patient community for an effective therapy for this fatal disease and a strong positive influence from patient advocacy groups on drug development, regulatory approval processes, and ultimately, drug uptake.
• The expected approval of repurposed molecules with broad specificity to treat DMD, such as Santhera Pharmaceutical's Catena (idebenone) and Eli Lilly's tadalafil.
• The label expansion of exon-51 skipping therapies (specifically, BioMarin/Prosensa Therapeutics' drisapersen and Sarepta Therapeutics' eteplirsen) to non-ambulant patients will substantially increase the size of the target patient pool for these drugs.
Read about the barriers to the growth of the DMD market http://www.marketinforesearch.com/opportunityanalyzer-duchenne-muscular-dystrophy-opportunity-market-analysis.html
Key Questions Answered
|
•
|
How will the DMD market landscape
change within the 2014-2019 forecast periods in the 6MM?
|
|
•
|
What are the most promising
late-stage pipeline drugs and how will their launch shape the future treatment
landscape in the DMD market?
|
|
•
|
How do the clinical and commercial
attributes of late-stage pipeline drugs compare to one another and against
existing treatment options?
|
|
•
|
Which patient population(s) are
most likely to be targeted by late-stage pipeline drugs?
|
If you have any questions about this or any of our other reports, please do not hesitate to contact me:
Neelima Waugh
Marketing Executive
press@marketinforesearch.com
No comments:
Post a Comment